权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles

使用免疫靶向上转换纳米颗粒的芯片级术中光学导航

基本信息

批准号：
10743477
负责人：
Mekhail Anwar
金额：
$ 65.53万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-15 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10743477
关键词：
Address Affinity Alloys Animal Model Antibodies Antibody Specificity Binding Biological Assay Breast Cancer Model Cancer Detection Cell Culture Techniques Clinical Coupled Deposition Detection Development Diffuse Disease Engineering Excision G-substrate Goals Image Image-Guided Surgery Imaging technology Immunoglobulin G Individual Label Lanthanoid Series Elements Lasers Left Lymph Node Involvement Malignant Neoplasms Malignant neoplasm of prostate Microscope Microscopic Modeling Modernization Mus Nanotechnology Nature Operative Surgical Procedures Optics Outcome Patients Photons Protein Engineering Proteins Recombinants Resectable Residual Cancers Residual Neoplasm Sensitivity and Specificity Silicon Speed Surface Surgical Instruments Surgical Models Surgical margins Technology Testing Thinness Time Tissue Sample Tissue Stains Tissue imaging Tissues Toxic effect Visible Radiation Visualization Xenograft Model absorption antibody engineering biomaterial compatibility cancer care cancer cell cancer imaging cancer risk cancer subtypes cancer surgery crosslink design detector diagnostic platform fluorophore imager imaging modality improved improved outcome instrument instrumentation integrated circuit light emission lymph nodes malignant breast neoplasm meter microscopic imaging molecular imaging nano nanocrystal nanoparticle nanoshell neoplastic cell new technology novel optical imaging pre-clinical sensor theranostics tool tumor two-photon

项目摘要

Project Summary/Abstract Residual cancer cells left behind following surgery increase the chance of cancer returning in almost every cancer subtype. The current inability to identify these tumor cells during surgery hinders cancer care across the spectrum, including breast and prostate cancers, as 20-40% of these patients suffer from positive margins, which doubles the risk of cancer returning. This proposal solves this problem through an original approach for ultrasensitive optical imaging of cancer cells in live tissue and during surgery. Current intraoperative imaging methods are unable to achieve high sensitivity both on the tissue surface and at depth due to inherent physical limits of both current optical probes and their requisite imagers. They are also too bulky to be integrated onto modern surgical tools, which could guide precision surgery with far greater accuracy than achievable today. Here, we address these dual challenges by introducing a wholly new imaging strategy integrating nanotechnology, protein engineering, and advanced imager design with the goal of real-time highly sensitive intraoperative imaging of cancer cells, both on the surface and at depth. We propose major advances in nanotechnology to redesign upconverting nanoparticles as optical probes that can be safely imaged in tissue, protein engineering to produce antibodies that selectively target the probes to tumor, and detector engineering to build an ultrathin imaging chip, directly integrated into surgical instrumentation. The combination of these novel technologies transforms instruments themselves into imagers to dramatically increase the sensitivity in identifying cancer cells, with the ultimate goal of being able to identify, in real time, all residual disease.

项目总结/文摘